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Prognostic value of the SYNTAX score in patients undergoing Primary
Percutaneous Coronary Intervention
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Ocaranza Sanchez, Diego Lopez Otero, Pablo Souto Castro, Rosa María Agra
Bermejo, Francisco Gude Sampedro, Jose Ramón Gonzalez Juanatey
Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain
Background: The SYNTAX score (SXs), designed to stratify outcomes in multivessel
percutaneous cornary intervention (PCI) and coronary artery bypass surgery (CABG),
has been validated in unselected populations undergoing elective PCI. Patients with
ST-segment elevation infarction (STEMI) were excluded from the original SXs
algorithm, the utility of using the SXs in this patient group remains undefinid. The aim
of this study was to evaluate the prognostic value of the SXs in a contemporary cohort
of patients admitted to our hospital with STEMI who were undergoing primary
percutaneous coronary intervention (PPCI).
Methods: The study included 310 consecutive patients undergoing PPCI between
January 2009 and December 2010. The median SXs was 15,6. We divided the patients
into tertiles: SXs (1)≤9; SXs(2) >9 and ≤18; SXs (3) >18.
Results: The median patient age was 66 years, 73% were men, 53% had hypertension,
and 26.5% had diabetes. Percutaneous access was via the radial approach in 72% of
the patients. The culprit artery was the left anterior descending in 42.7% of the patients,
31% had three-vessel disease, and a stent was implanted in 90% of the patients. The
median duration of follow-up was 10 months, and 12,6% of the patients died: 12,8%
in SXs (1), 30,8% in SXs (2), and 56,4% in SXs (3) (P<0.05)(See Image). The
incidence of major adverse cardiovascular events (MACE) at the end of the follow-up
was 18%: 12,8% in SXs (1), 27,3% in SXs (2), and 54,5% in SXs (3) (P<0.05). The
SXs levels were an independent determinant of mortality in a multivariate analysis
[HR IC 95%: 1,071 (1,033-1,110),P<0.05], and were an independent determinant of
MACE [HR IC 95%: 1,057 (1,025-1,091),P<0.05].
Conclusion: The SXs provides important prognostic information regarding mortality
and major adverse cardiovascular events in a cohort of patients with STEMI who were
undergoing PPCI.
TCT-360
Use Of Thrombectomy Devices In Primary Percutaneous Coronary
Intervention
Neville Kukreja1, Charis Costopoulos1, Diana Gorog1, Carlo Di Mario2
1East and North Hertfordshire NHS Trust, Stevenage, United Kingdom; 2Royal
Brompton and Harefiled NHS Trust, London, United Kingdom
Background: Primary percutaneous coronary intervention (PPCI) is the treatment of
choice for ST-elevation myocardial infarction (STEMI). Although this often achieves
Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow in the affected epicardial
vessel, myocardial re-perfusion is not fully restored in a significant percentage of
patients, a phenomenon known as no or slow-reflow. Thrombectomy aims to reduce
this by minimizing distal embolization.
Methods: We performed a computerized search on electronic medical databases using
the terms “thrombectomy” and “thrombus aspiration” to identify randomized control
trials (RCTs) that used adjunctive thrombectomy in PPCI for STEMI. Data from 22
eligible RCTs was used for the meta-analysis. Thrombectomy devices were divided
into manual and mechanical groups by the presence or absence of a motorized system.
Angiographic and electrophysiological end-points were TIMI flow, myocardial blush
grade (MBG) and ST-segment resolution (STR) respectively. Clinical outcomes were
death and a composite of death, MI or stroke.
Results: The risk profile of the treatment and control groups was similar.
Thrombectomy device delivery was successful in most cases. Results showed that
manual thrombectomy in PPCI is associated with better STR (p< 0.00001), MBG (p<
0.00001) and TIMI flow (p=0.01) in comparison to standard PPCI. There was a
significant reduction in death (p=0.04), death, recurrent MI or stroke (p=0.05).
Mechanical thrombectomy improved STR (p=0.005) but not MBG (p=0.19), TIMI
flow (p=0.91) or clinical outcomes (death p= 0.90, death, MI or stroke p=0.71).
Conclusion: The majority of published meta-analyses that studied the role of
adjunctive thrombectomy in PPCI did not distinguish between the use of manual and
mechanical devices. In cases where aspiration thrombectomy without active thrombus
fragmentation was examined devices driven by a motor were included. This up-to-date
meta-analysis demonstrates that manual but not mechanical thrombectomy in PPCI
improves surrogate markers of reperfusion as well as clinical outcomes.
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Safety and Efficacy of Biodegradable vs Durable Polymer Drug Eluting Stents:
Evidence from a Meta-analysis of Randomized Trials
Eliano Pio Navarese1, 2, Jacek Kubica2, Stefano De Servi3, C. Michael Gibson4,
Carlo Di Mario7, Felicita Andreotti5, Massimo Margheri6, Leonardo Bolognese8,
Fausto Castriota1
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(Ravenna), Italy; 2Nicolaus Copernicus University, Bydgoszcz, Poland; 3Civic
Hospital, Legnano, Milan, Italy; 4Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA; 5Catholic University, Rome, Italy; 6Azienda
Ospedaliera Ravenna, Ravenna, Italy; 7Royal Brompton Hospital, Imperical
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Background: Drug eluting stents (DES) are a major advance in interventional
cardiology; however concerns have been raised regarding their long-term safety due
to the permanent nature of the polymer. New generation stents with biodegradable
polymers (BDS) have been recently developed. The aim of this study was to perform
a meta-analysis of randomized controlled trials (RCTs) comparing the safety and
efficacy profile of BDS vs durable polymer DES.
Methods: Medline/CENTRAL and Web were searched for RCTs comparing safety
and efficacy of BDS vs DES. Safety endpoints were mortality, myocardial infarction
(MI), overall major adverse cardiac events and stent thrombosis (ST). Efficacy
endpoints were target vessel revascularization (TVR), target lesion revascularization
(TLR) and six-month in-stent late loss (ISLL).
Results: The meta-analysis included eight RCTs (N= 7481). At a median follow-up of
9 months, as compared to DES, BDS use did not increase mortality (OR [95% CI] =
0.91 [0.69 - 1.22], p = 0.53) or MI (OR [95% CI] = 1.14 [0.90 - 1.44], p = 0.29). Rate
of late/very late ST was significantly reduced in BDS patients (OR [95% CI] = 0.60
[0.39 - 0.92], p = 0.02), as was six-month ISLL (mean difference [95% CI] = -0.07 [-
0.12; -0.02] mm, p = 0.004) in comparison with DES patients. Rates of TVR and TLR
were comparable between BDS and DES.
Conclusion: This meta-analysis showed safety and efficacy of BDS that, as compared
with DES, significantly reduced the incidence of late/very late ST and ISLL, without
increasing the rates of death and MI.
TCT-362
The Impact of LV function on the Mortality of Patients undergoing
Transcatheter Aortic Valve Implantation
Yacine Elhmidi, Nicolo Piazza, Sabine Bleiziffer, Anke Opitz, Hendrik Ruge,
Domenico Mazzitelli, Bernhard Voss, Rüdiger Lange
German Heart Center, Department of cardiovascular Surgery, Munich, Germany
Background: Aortic stenosis patients with left ventricular dysfunction are at increased
risk for morbidity and mortality following surgical aortic valve replacemement. There
is little published data regarding the outcomes of patients with severe aortic stenosis
and left ventricular (LV) dysfunction undergoing TAVI.
Methods: Between November 2007 and January 2010, a total of 504 consecutive
patients were enrolled. Patients were stratified according to left ventricular function
as follows: normal LV function (LVEF >50%), moderate LV dysfunction (LVEF 35-
50%) and severe LV dysfunction (LVEF <35%). The baseline and clinical outcomes,
up to 6 months, were subsequently compared among the 3 patient groups. Furthermore,
we compared survival outcomes between severe LV dysfunction patients with high
(>40 mmHg) and low (<40 mmHg) transaortic mean valve gradients (MG).
Results: 324 patients (64%) had normal LV function, 111 patients (22%) had moderate
LV dysfunction, and 70 patients (14%) had severe LV dysfunction. In the severe LV
dysfunction group, 38 patients had a mean transaortic valve gradient >40 mm HG and
30 patients had <40 mmHg. As compared with patients with normal LV function, those
with severe LV dysfunction were more likely to be male, have higher STS and logistic
EurosSCORES, have more coronary artery disease and previous coronary artery bypass
surgery, higher median BNP levels, lower mean transaortic valve gradients and greater
aortic valve area. The 6-month mortality was 12% higher in patients with severe LV
dysfunction than in those with normal LV function (27 vs. 15%, p-value=0.03). In the
severe LV dysfunction group, patients with low transaortic valve gradients had a nearly
4-fold higher 6-month mortality than patients with high gradients (38 vs. 10%, p-value
= 0.01).
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Conclusion: Patients with severe aortic stenosis and LV dysfunction undergoing TAVI
have worse 6-month survival outcomes than patients with normal LV function. In those
patients with LV dysfunction, a mean transaortic valve gradient <40 mmHg was
associated with a higher mortality than if the gradient was >40 mmHg.
TCT-363
Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial
Infarction Undergoing a Primary PCI Management Strategy: Analysis from the
HORIZONS-AMI Trial
Eugenia Nikolsky5, 1, Bernard J Gersh2, Dangas D George3, Shing-Chiu Wong4, Ke
Xu5, Martin Fahy5, Roxana Mehran5, Gregg W Stone5
1Cardiology, Rambam Medical Center, Haifa, Israel; 2Mayo Clinic, Rochester, MN;
3Mount Sinai Hospital, New York, NY; 4Weill Cornell Medical Center, New York, NY;
5Columbia University and the Cardiovascular Research Foundation, New York, NY
Background: Cerebrovascular accident (CVA) is a major adverse event in pts with
STEMI. The incidence and predictors of CVA in pts undergoing a primary PCI
management strategy have been incompletely characterized.
Methods: In the HORIZONS-AMI trial, following emergent coronary arteriography
in 3,602 pts with STEMI, the principal management was by PCI in 3347 (92.9%),
CABG in 64 (1.8%) and medical therapy in 189 (5.2%). A CVA during the 3-year
follow-up period developed in 72 pts(2.0%), including 63 (1.7%) who had a stroke
and 12 (0.3%) who had a transient ischemic attack (TIA). Three pts had both stroke
and TIA.
Results: The CVA occurred in 26 pts(36.1%) within 30 days, in 20 pts(27.8%) between
30 days and 1 year, and in 26 pts(36.1%) between 1 and 3 years. Stroke was ischemic
in origin in 58/63 pts (92.1%) and hemorrhagic in 5/63 pts (7.9%). By principle
management strategy, CVA developed in 1.8%, 14.1% and 1.6% pts triaged to primary
PCI, CABG and medical therapy, respectively (p=0.06). By multivariable analysis,
occurrence of CVA at 3 years was associated with older age (HR=1.72 per 10 years
increase, p=0.006), LVEF <40% (HR=2.59, p=0.04), and performance of CABG within
30 days (HR=5.49, p=0.002). CVA was associated with strikingly increased rates of
3-year mortality (20.5% vs. 6.5%, p<0.0001). The risk of 3-year mortality in pts with
CVA was greater in pts with true stroke compared to those only with TIA (22.2% vs.
0%, P=0.14), but was comparable in pts in whom the stroke etiology was ischemic vs.
hemorrhagic (22.4% vs. 20.0%, HR[95%CI]=1.08[0.14,8.25], p=0.94). In a time
updated covariate adjusted multivariable analysis, stroke was an independent predictor
of 3-year mortality (HR[95%CI]=2.11[1.15,3.89], p=0.02].
Conclusion: In pts with STEMI undergoing a primary PCI management strategy, the
risk of developing a CVA within 3 years is relatively low in those treated with PCI or
medical therapy after angiographic triage, but may be frequent after CABG. Ischemic
and hemorrhagic stroke after STEMI are associated with substantial mortality.
TCT-364
The Association of Pre-infarction Angina, Pre-procedural Thrombolysis in
Myocardial Infarction Flow and Collateral Flow with Myocardial Salvage in
Patients with ST-Segment Elevation Myocardial Infarction
Jacob T Lønborg1, Niels Vejlstrup1, Henning Kelbæk1, Hans E Bøtker2, Won Y Kim2,
Lene Holmvang1, Erik Jørgensen1, Steffen Helqvist1, Peter Clemmensen1, Kari
Saunamaki1, Leif Thuesen2, Lars R Krusell2, Thomas Engstrøm1
1Department of Cardiology, Rigshospitalet, University Hospital Copenhagen,
Copenhagen, Denmark; 2Skejby, Aarhus University Hospital, Arhus, Denmark
Background: In patients with ST-segment elevation myocardial infarction (STEMI)
periods of ischemia assessed by angina preceding the infarction (pre-infarction angina),
pre-procedural TIMI flow and collateral flow to the infarct related artery are suggested
to be related to prognosis. We evaluated the effect of pre-infarction angina, pre-
procedural TIMI flow and collateral flow on myocardial salvage (MSI) by cardiac
magnetic resonance (CMR) in STEMI patients treated with primary percutaneous
coronary intervention.
Methods: In 198 patients with STEMI myocardial area at risk was measured within
1-7 days and final infarct size 90±21 days after STEMI. The primary endpoint was
MSI: (Area at risk – infarct size) / area at risk.
Results: Patients with one or more incidences of pre-infarction angina had higher MSI
than patients without (0.80 (IQR 0.67-0.86) versus 0.72 (0.61-0.80), p=0.005). MSI
was significantly different between pre-procedural TIMI flow groups 0/1, 2 and 3 (0.69
(0.59-0.76), 0.78 (0.68-0.86) versus 0.85 (0.77-0.91); p<0.001). Post-hoc analysis
showed that TIMI flow 0/1 had smaller MSI compared to TIMI flow 2 and 3 (p<0.01).
Furthermore, TIMI flow 2 was associated with smaller MSI than TIMI flow 3 (p<0.05).
Collateral flow did not change MSI (0.69 (0.59-0.76) versus 0.71 (0.65-0.78); p=0.45).
Conclusion: Pre-infarction angina increases MSI in STEMI patients supporting the
theory that pre-infarction angina leads to ischemic preconditioning. Pre-procedural
TIMI flow is an important predictor for MSI and patients with TIMI flow 2 is at
intermediary risk. Collateral flow does not change MSI.
TCT-365
Primary Percutaneous Coronary Intervention With Off-Site Cardiac Surgery
Backup in Unselected Patients With ST-segment-Elevation Myocardial
Infarction: the RIvoli ST-segment Elevation Myocardial Infarction (RISTEMI)
registry
Francesco Tomassini, Andrea Gagnor, Emanuele Tizzani, Paolo Tizzani, Vincenzo
Infantino, Ferdinando Varbella
Cardiology, Infermi Hospital, Rivoli, Italy
Background: Primary percutaneous coronary intervention (PPCI) is the preferred
reperfusion strategy for patients (pts) with ST-segment-elevation myocardial infarction
(STEMI), but some concerns still remain about its safety and efficacy in centers without
cardiac surgery on-site (SOS).
Methods: The Infermi Hospital is a community hospital with a high volume
catheterization laboratory (CL)(>800 total PCI and >150 PPCI/year) without SOS and
provides a network-wide PPCI service to a population of 583.000 in a 24/7/365 fashion
within easy reach of SOS hospitals in Turin city (14 Km). We collected data about all
consecutive pts with STEMI within 12 hours admitted to our CL and analyzed clinical
and procedural characteristics as well as in-hospital outcomes of pts who underwent
PPCI.
Results: From September 2001 to June 2010, 1302 STEMI pts underwent urgent
coronary angiography. Of these 45 (3.4%) did not present significant coronary artery
disease (CAD) and were managed medically; 6 (0.5%) presented severe CAD and were
sent to surgery and 1251 (96.1%, mean age 65±12 years, 25.1% females, 23%
diabetics) underwent PPCI. One hundred ninety-eight pts (15.8%) presented with shock
(CS). Procedural success was 93.7%. Overall in-hospital death (IHD) was 6.9%.
Multivariate predictors of IHD were: age ≥75 years (hazard ratio 3.96, 95% CI 1.89-
8.32, p=0.0003), ejection fraction <40% (hazard ratio 1.35, 95% CI 1.05-1.72, p=0.02),
CS at presentation (hazard ratio 33.40, 95% CI 11.10-100.44, p<0.0001), anterior
infarction (hazard ratio 1.82, 95% CI 1.04-3.17, p=0.036) and oro-tracheal intubation
(hazard ratio 37.04, 95% CI 6.0-228.45, p=0.0001). Total ischemic time ≤ 3 hours led
to a favorable outcome (hazard ratio 0.55, 95% CI 0.30-1.01, p=0.05).
Conclusion: PPCI is a reperfusion strategy feasible and effective in unselected high-
risk STEMI pts even in hospitals without SOS, provided that a high volume of routine
and emergency interventional procedures is maintained.
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Prognostic Role of Thrombus Aspiration and IIb/IIIa inhibitors during
Primary Percutaneous Coronary Intervention
Stylianos A. Pyxaras1, Serena Rakar1, Andrea Perkan1, Sara Santangelo1, Giancarlo
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2Cardiology Unit, Gorizia Hospital, Gorizia, Italy; 3Emergency Department,
University Hospital of Trieste, Trieste, Italy; 4Emergency Services, ASS 1 Triestina,
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Background: The beneficial role of adjunctive antithrombotic treatments, such as
manual thrombus aspiration (TA) and Glycoprotein IIb/IIIa inhibitors (GPI) was
previously confirmed in the setting of Primary Primary Percutaneous Coronary
Intervention (PPCI). Still, trials regarding GPI did not consider patients undergoing
TA, while all major studies on TA concerned patient populations prevalently treated
with GPI.
Methods: From January 2007 to December 2009, 448 STEMI patients were
consecutively enroled according to a 2×2 factorial design into 1 of the 4 groups:
standard PPCI, PCI with thrombus aspiration (TA), PPCI with GPI infusion, and PPCI
with both treatments (TA+GPI).
Results: . A post procedural TIMI flow 2-3 was present in 91% in the standard PPCI
group, 95% in the GPI group, 95% in the TA group, and 98.8% in the TA+GPI group
(p=0.026). At 30 days of follow up, the cumulative incidence of death and re-infarction
was 5% in patients treated TA and GPI, 10% in patients treated with only TA, 15% in
patients treated only with GPI, and 16% in patients treated with standard PPCI
(p=0.036). Long term mortality differed significantly between patients treated with
both TA and GPI and patients treated with standard PPCI (7% vs 17.2%, p=0.012). At
multivariate analysis, age (HR 1.058, CI 1.015-1.103, p=0.008), III-IV Killip Class
(HR 12.663, CI 4.772-33.602, p<0.001), TA (HR 0.355, CI 0.138-0.914, p=0.032), left
ventricular ejection fraction<45% (HR 4.787, CI 1.941-11.807, p=0.001), and increased
CK-MB values (HR 1.002, CI 1-1.003, p=0.007) emerged as independent predictors
for overall mortality.
Conclusion: In STEMI patients undergoing PPCI, the combined application of
thrombus aspiration and abciximab was associated with lower short term mortality and
reinfarction rates and with an improved long term outcome. TA, but not GPI, emerged
as an independent predictor of long term survival.
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